HRS-9231 Injection

DRUG2 trials

Sponsors

Shanghai Shengdi Pharmaceutical Co., Ltd

Conditions

For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions

Phase 3

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions

CompletedNCT07275814

Shanghai Shengdi Pharmaceutical Co., LtdFor Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions

Start: 2025-11-17End: 2026-06-17Updated: 2026-06-30

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions

CompletedNCT07275723

Shanghai Shengdi Pharmaceutical Co., LtdFor Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)

Start: 2025-11-14End: 2026-06-09Updated: 2026-06-30